systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-697Research ArticleСТАТЬИARTICLESКлиническая фармакология сартанов:
класс-эффект и фармакодинамические
особенности препаратовЗахароваН. В.noemail@neicon.ruКузьмина-КрутецкаяС. Р.noemail@neicon.ruСанкт-Петербургская медицинская академия последипломного образованияRussian Federation201109022023831016Copyright © Захарова Н.В., Кузьмина-Крутецкая С.Р., 20232023Захарова Н.В., Кузьмина-Крутецкая С.Р.Захарова Н.В., Кузьмина-Крутецкая С.Р.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/697ReferencesBrunner HR, Kirsman DJ, Sealey JE et al. Hypertension of renal origin:evidence for two different mechanisms. Science 1971; 174: 1344-6.Brunner HR, Kirsman DJ, Sealey JE et al. Hypertension of renal origin:evidence for two different mechanisms. Science 1971; 174: 1344-6.Brunner HR, Gavras H, Laragh JH et al. Angiotensin-II blockade in man by Sar1-Ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; 2: 1045.Brunner HR, Gavras H, Laragh JH et al. Angiotensin-II blockade in man by Sar1-Ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; 2: 1045.Bergsma DJ, Ellis C, Kumar C et al. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992; 183: 989-95.Bergsma DJ, Ellis C, Kumar C et al. Cloning and characterization of a human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992; 183: 989-95.Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л. и др. Фармакоэпидемиология артериальной гипертонии в России (по результатам фармакоэпидемиологического исследования ПИФАГОР III. Рос. кардиол. журн. 2011; 2: 9-17.Леонова М.В., Белоусов Ю.Б., Штейнберг Л.Л. и др. Фармакоэпидемиология артериальной гипертонии в России (по результатам фармакоэпидемиологического исследования ПИФАГОР III. Рос. кардиол. журн. 2011; 2: 9-17.Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 (Suppl. 3): S13-S22.Dzau VJ, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11 (Suppl. 3): S13-S22.Urata K, Kinoshita A, Misono K et al. Identification of a highly specific chymase as the major angiotensin-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-82.Urata K, Kinoshita A, Misono K et al. Identification of a highly specific chymase as the major angiotensin-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-82.Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation 2001; 103: 904-12.Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation 2001; 103: 904-12.Ohkubo N, Matsubara H, Nozawa Y et al. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96: 3954-62.Ohkubo N, Matsubara H, Nozawa Y et al. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96: 3954-62.Ritter JM. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension. BMJ 2011; 342: d1673 doi: 10.1136/bmj.d1673.Ritter JM. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension. BMJ 2011; 342: d1673 doi: 10.1136/bmj.d1673.Miura S, Karnik S and Saku K. Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin-Angiotensin-Aldosterone Syst 2011; 12: 1.Miura S, Karnik S and Saku K. Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin-Angiotensin-Aldosterone Syst 2011; 12: 1.Doulton T, He F and MacGregor G. MacGregor Angiotensin Receptor Blockade in Hypertension. Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension. Hypertension 2005; 45: 880-6.Doulton T, He F and MacGregor G. MacGregor Angiotensin Receptor Blockade in Hypertension. Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension. Hypertension 2005; 45: 880-6.Azilsartan medoxomil (Edarbi) the eighth ARB. Med Lett Drugs Ther 2011; 16 (53): 1364.Azilsartan medoxomil (Edarbi) the eighth ARB. Med Lett Drugs Ther 2011; 16 (53): 1364.Le MT, De Backer JP, Hunyady L et al. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. Eur J Pharmacol 2005; 513 (1-2): 35-45.Le MT, De Backer JP, Hunyady L et al. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. Eur J Pharmacol 2005; 513 (1-2): 35-45.Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302 (2): 237-43.Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302 (2): 237-43.Bhuiyan MA, Ishiguro M, Hossain M et al. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci 2009; 85 (3, 4): 136.Bhuiyan MA, Ishiguro M, Hossain M et al. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci 2009; 85 (3, 4): 136.Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801-8.Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801-8.Westerink J, Visseren F. Cardiovasc Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011; 10: 13.Westerink J, Visseren F. Cardiovasc Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011; 10: 13.Bangalore S. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342: d2234.Bangalore S. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342: d2234.Ishii H, Tsukada T, Yoshida M. Angiotensin II Type-I Receptor Blocker, Candesartan, Improves Brachial-Ankle Pulse Wave Velocity Independent of Its Blood Pressure Lowering Effects in Type 2 Diabetes Patients. J Soc Int Med 2008; 47: 2013-8.Ishii H, Tsukada T, Yoshida M. Angiotensin II Type-I Receptor Blocker, Candesartan, Improves Brachial-Ankle Pulse Wave Velocity Independent of Its Blood Pressure Lowering Effects in Type 2 Diabetes Patients. J Soc Int Med 2008; 47: 2013-8.Izuhara Y, Sada T, Yanagisawa H et al. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008; 28 (10): 1767-73.Izuhara Y, Sada T, Yanagisawa H et al. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008; 28 (10): 1767-73.Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens.Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens.Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. (рабочая группа). Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5-27.Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. (рабочая группа). Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 3: 5-27.Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16.Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16.Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772.Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772.Lee VC, Rhew DC, Dylan M et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693.Lee VC, Rhew DC, Dylan M et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141: 693.Eklind-Cervenka M, Benson L, Dahlström U et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011; 305: 175.Eklind-Cervenka M, Benson L, Dahlström U et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011; 305: 175.Weir RA, McMurray JJ, Puu M et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail 2008; 10 (2): 157-63.Weir RA, McMurray JJ, Puu M et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail 2008; 10 (2): 157-63.Drazner MH, Rame JE, Marino EK et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: 2207.Drazner MH, Rame JE, Marino EK et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: 2207.Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41.Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41.Os I, Franco V, Kjeldsen SE et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008; 51: 1103.Os I, Franco V, Kjeldsen SE et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008; 51: 1103.Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 2008; 4: 67.Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 2008; 4: 67.Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777.Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777.Yamashita T, Inoue H, Okumura K et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13 (4): 473-9.Yamashita T, Inoue H, Okumura K et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13 (4): 473-9.Tissot AC, Maurer P, Nussberger J et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371: 821.Tissot AC, Maurer P, Nussberger J et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008; 371: 821.
The authors declare that there are no conflicts of interest present.